BSD gets IDE for enhancement to cancer system
This article was originally published in Clinica
Executive Summary
The US FDA has given BSD Medical the go-ahead to test several enhancements to its BSD-2000 hyperthermia-based cancer treatment system, which the firm says are crucial to its strategic marketing plan for introducing the product line commercially.